Drug Trial Radar · NCT07938034
A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal Function
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Jul 15, 2027
Study completion Sep 15, 2027
Sponsor
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with moderate, and severe renal impairment compared to participants with normal renal function.
Conditions
- Renal Impairment
Interventions
SYH2053Drug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Time Frame: Pre-dose and multiple timepoints up to 4 days
- Area under the curve of the plasma concentration (AUC)Time frame: Pre-dose and multiple timepoints up to 4 days
- Time to reach maximum plasma concentration (Tmax)Time frame: Pre-dose and multiple timepoints up to 4 days
- Terminal half-life (t1/2)Time frame: Pre-dose and multiple timepoints up to 4 days
- Apparent total clearance (CL/F)Time frame: Pre-dose and multiple timepoints up to 4 days
- Apparent volume of distribution (Vz/F)Time frame: Pre-dose and multiple timepoints up to 4 days
- Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-doseTime frame: Pre-dose and multiple timepoints up to 4 days
- Fraction excreted (fe) of SYH2053 over 72 hours post-doseTime frame: Pre-dose and multiple timepoints up to 4 days
- Renal clearance (CLr) of SYH2053Time frame: Pre-dose and multiple timepoints up to 4 days
- The serum Low-density lipoprotein cholesterol (LDL-C) levelTime frame: through study completion, an average of 6 months
- The serum PCSK9 levelTime frame: through study completion, an average of 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.